Search - tctmd.com

Displaying 181 - 200 of 402

Sort: Relevancy | Date

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Update on RCTs in FMR, and First Report of the COAPT Roll-in Patients

Presenter: Alec S. Vahanian, Ralph Stephan von Bardeleben, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Presenter: Vivek Y. Reddy, Steven J. Yakubov, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Presenter: Peter Juni, E. Magnus Ohman, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation TCT 2016

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Ziad A. Ali

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Presentation TCT 2015

Debate: Should Our Patients Receive BRS Rather Than Metallic DES TODAY? Yes, the 1-Year Results Are Very Close, and the Late Outcomes Will Be Superior Our Patients Cant Wait for the Proof!

Presenter: Thomas F. Luscher, Gregg W. Stone, Ashok Seth

October 15, 2015

Presentation TCT 2015

Case Resolution: How We Treated a Clinically High-Risk and Anatomically Complex Left Main Patient (With Long-term Follow-up)

Presenter: Davide Capodanno, Gregg W. Stone, Nicholas J. Lembo

October 15, 2015

Presentation TCT 2015

Case Introduction: PCI or CABG? A Clinically High-Risk and Anatomically Complex Left Main Patient

Presenter: Davide Capodanno, Gregg W. Stone, Nicholas J. Lembo

October 15, 2015

Presentation TCT 2015

Who Should Undergo LM PCI Today? US and EU Guidelines and AUC Review

Presenter: Davide Capodanno, Gregg W. Stone, Ajay J. Kirtane

October 15, 2015

Presentation TCT 2015

Long-term Results of PCI vs CABG in 4,046 Patients With Left Main Disease: Fu Wai Experience

Presenter: Davide Capodanno, Gregg W. Stone, Bo Xu

October 15, 2015

Presentation TCT 2015

PCI vs CABG for LM Disease: New Insights From Syntax LM to Help Choose

Presenter: Davide Capodanno, Gregg W. Stone, Patrick W. Serruys

October 15, 2015

Presentation TCT 2015

Left Main PCI vs CABG: Fifteen-Year Results From the Asan Medical Center and 5-Year Results From PRECOMBAT

Presenter: Davide Capodanno, Gregg W. Stone, Jung-Min Ahn

October 15, 2015

Presentation TCT 2015

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Presenter: Chuck Simonton, Gregg W. Stone

October 14, 2015

Presentation TCT 2015

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Presenter: Andrew Farb, Gregg W. Stone, John A. Spertus

October 14, 2015

Presentation TCT 2015

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Presenter: Andrew Farb, Gregg W. Stone, Michael C. John

October 14, 2015

Advertisement

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Update on RCTs in FMR, and First Report of the COAPT Roll-in Patients

Early and Late Results With the Wavecrest LAA Occluder (and Future Studies)

Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint?

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Debate: Should Our Patients Receive BRS Rather Than Metallic DES TODAY? Yes, the 1-Year Results Are Very Close, and the Late Outcomes Will Be Superior Our Patients Cant Wait for the Proof!

Case Resolution: How We Treated a Clinically High-Risk and Anatomically Complex Left Main Patient (With Long-term Follow-up)

Case Introduction: PCI or CABG? A Clinically High-Risk and Anatomically Complex Left Main Patient

Who Should Undergo LM PCI Today? US and EU Guidelines and AUC Review

Long-term Results of PCI vs CABG in 4,046 Patients With Left Main Disease: Fu Wai Experience

PCI vs CABG for LM Disease: New Insights From Syntax LM to Help Choose

Left Main PCI vs CABG: Fifteen-Year Results From the Asan Medical Center and 5-Year Results From PRECOMBAT

Possible Clinical Trial Designs to Demonstrate the Relative Benefits of BRS vs Permanent Platform DES

Incorporating Quality-of-Life and Patient-Oriented Outcomes in the Device Regulatory Approval Process

Key Elements of BRS Nonclinical Testing to Support IDE Approval

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content